Applied Clinical Trials-12-01-2020

Recent webcast addresses what organizations can do to prepare for the next revision of ICH E6.

Looking back on regulatory challenges created by COVID in 2020.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Spotlight on clinical trials created by COVID-19 pandemic has forced regulatory officials around the world to expand disclosure requirements on results.

COVID-19 pandemic forces compliancy within organizations following FDA’s 2018 revision of Good Clinical Practice in federal registry.

Click the title above for a link to open the Applied Clinical Trials December 2020 issue in an interactive PDF format.

Eliminating barriers to engage underrepresented populations.

Clinical operations professionals, burdened by lack of data standardization, turn to technology in hopes of streamlining regulatory processes for the future.

Regulatory concerns remain despite industry's quick adaptation of decentralized trials.

Battle for trust ensues as vaccines are set for approval.

While the UK's departure from the EU is imminent, NICE will continue to influence thinking around the continent.

Comparing late-stage COVID-19 vaccine trials to historical practices.

Radiomics can help life sciences companies realize the full value of their imaging pipelines.

Past decades have shown gender-based differences in clinical trial results are often overlooked when considering safety and effectiveness.